Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.48 |
| ▸ | PNMT | P11086 | 4/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554736 | 1.00 | CD274 (0.48) | CD274PNMTCD44MAOBADRA2A | |
| Hydrochloric Acid SCHEMBL18554685 | 0.99 | CD274 (0.47) | CD274PNMTCD44MAOBADRA2A | |
| SCHEMBL18555017 | 0.82 | PNMT (0.39) | CD274PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL24842428 | 0.81 | CD274 (0.49) | CD274PNMTCD44MAOBADRA2A | |
| SCHEMBL18554652 | 0.80 | CYP3A4 (0.52) | CD274PNMTCD44MAOBADRA2A | |
| SCHEMBL19914887 | 0.78 | HTR2C (0.53) | ADRA2AADRA2BADRA2CHTR2CHTR2B | |
| SCHEMBL14116965 | 0.77 | PNMT (0.47) | CD274PNMTCD44MAOBADRA2A | |
| SCHEMBL20909790 | 0.77 | PNMT (0.47) | CD274PNMTCD44MAOBADRA2A | |
| SCHEMBL26232606 | 0.77 | CD274 (0.46) | CD274PNMTCD44MAOBASIC3 | |
| SCHEMBL18554655 | 0.76 | CD274 (0.53) | CD274PNMTCD44MAOBADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | LDLR, PCSK9, CETP | CD274 983/4885PNMT 4172/4885CD44 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.